$16.6 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 136 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 146.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
IQV | Buy | IQVIA HLDGS INC | $724,475,000 | +30.3% | 4,043,506 | +14.7% | 4.36% | +13.3% |
TMUS | Buy | T-MOBILE US INC | $532,547,000 | +28.0% | 3,949,181 | +8.6% | 3.20% | +11.3% |
TMO | Buy | THERMO FISHER SCIENTIFIC INC | $518,994,000 | +7.3% | 1,114,248 | +1.7% | 3.12% | -6.7% |
SPY | New | SPDR S&P 500 ETF TRput | $510,346,000 | – | 1,365,000 | +100.0% | 3.07% | – |
V | Buy | VISA INC | $487,353,000 | +42.0% | 2,228,104 | +29.8% | 2.93% | +23.4% |
AON | Buy | AON PLC | $479,903,000 | +32.4% | 2,271,514 | +29.3% | 2.89% | +15.2% |
BSX | Buy | BOSTON SCIENTIFIC CORP | $475,918,000 | +50.5% | 13,238,319 | +60.0% | 2.86% | +30.9% |
ARMK | New | ARAMARK | $424,202,000 | – | 11,023,949 | +100.0% | 2.55% | – |
MSFT | Buy | MICROSOFT CORP | $391,052,000 | +20.7% | 1,758,168 | +14.1% | 2.35% | +4.9% |
XLNX | New | XILINX INC | $362,364,000 | – | 2,556,000 | +100.0% | 2.18% | – |
ALXN | New | ALEXION PHARMACEUTICALS INC | $351,056,000 | – | 2,246,900 | +100.0% | 2.11% | – |
RTX | New | RAYTHEON TECHNOLOGIES CORP | $324,820,000 | – | 4,542,306 | +100.0% | 1.95% | – |
CRM | Buy | SALESFORCE COM INC | $313,555,000 | +78.7% | 1,409,045 | +101.8% | 1.89% | +55.4% |
IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $278,400,000 | +42.0% | 6,000,000 | +0.8% | 1.67% | +23.5% |
AVGO | New | BROADCOM INC | $272,778,000 | – | 622,995 | +100.0% | 1.64% | – |
BX | Buy | BLACKSTONE GROUP INC | $252,233,000 | +26.2% | 3,891,886 | +1.6% | 1.52% | +9.7% |
EXEL | Buy | EXELIXIS INC | $220,770,000 | -16.0% | 11,000,000 | +2.3% | 1.33% | -27.0% |
WORK | New | SLACK TECHNOLOGIES INC | $207,496,000 | – | 4,912,300 | +100.0% | 1.25% | – |
WLTW | Buy | WILLIS TOWERS WATSON PLC LTD | $202,780,000 | +1842.2% | 962,500 | +1825.0% | 1.22% | +1594.4% |
IPHI | New | INPHI CORP | $198,951,000 | – | 1,239,800 | +100.0% | 1.20% | – |
BABA | Buy | ALIBABA GROUP HLDG LTDsponsored ads | $198,589,000 | +10.3% | 853,300 | +39.3% | 1.19% | -4.2% |
HLT | Buy | HILTON WORLDWIDE HLDGS INC | $182,515,000 | +38.4% | 1,640,437 | +6.1% | 1.10% | +20.4% |
QGEN | New | QIAGEN NV | $172,120,000 | – | 3,256,771 | +100.0% | 1.04% | – |
MXIM | Buy | MAXIM INTEGRATED PRODS INC | $136,734,000 | +64.4% | 1,542,400 | +25.4% | 0.82% | +43.0% |
AMRS | Buy | AMYRIS INC | $108,063,000 | +164.3% | 17,500,000 | +25.0% | 0.65% | +129.7% |
Buy | MOMO INCnote 1.250% 7/0 | $93,459,000 | +13.2% | 110,077,000 | +5.8% | 0.56% | -1.6% | |
LU | New | LUFAX HOLDING LTD | $76,080,000 | – | 5,357,750 | +100.0% | 0.46% | – |
Buy | IQIYI INCnote 2.000% 4/0 | $71,760,000 | +21.4% | 81,762,000 | +32.4% | 0.43% | +5.6% | |
FGEN | Buy | FIBROGEN INC | $70,471,000 | -7.4% | 1,900,000 | +2.7% | 0.42% | -19.4% |
BCAB | New | BIOATLA INC | $66,900,000 | – | 1,967,060 | +100.0% | 0.40% | – |
GBIO | Buy | GENERATION BIO CO | $64,321,000 | -1.9% | 2,268,819 | +7.0% | 0.39% | -14.6% |
ARNA | Buy | ARENA PHARMACEUTICALS INC | $57,623,000 | +22.3% | 750,000 | +19.1% | 0.35% | +6.4% |
CYTK | Buy | CYTOKINETICS INC | $49,872,000 | +7.1% | 2,400,000 | +11.6% | 0.30% | -6.8% |
CLGX | Buy | CORELOGIC INC | $44,384,000 | +90.1% | 574,028 | +66.4% | 0.27% | +65.8% |
IONS | New | IONIS PHARMACEUTICALS INC | $42,405,000 | – | 750,000 | +100.0% | 0.26% | – |
CARA | Buy | CARA THERAPEUTICS INC | $37,295,000 | +30.3% | 2,465,000 | +9.6% | 0.22% | +13.1% |
New | INSMED INCnote 1.750% 1/1 | $36,552,000 | – | 32,500,000 | +100.0% | 0.22% | – | |
KRYS | Buy | KRYSTAL BIOTECH INC | $31,500,000 | +54.0% | 525,000 | +10.5% | 0.19% | +34.0% |
NVAX | New | NOVAVAX INC | $30,665,000 | – | 275,000 | +100.0% | 0.18% | – |
PANA | New | PANACEA ACQUISITION CORPcl a | $29,250,000 | – | 2,500,000 | +100.0% | 0.18% | – |
FOLD | New | AMICUS THERAPEUTICS INC | $28,863,000 | – | 1,250,000 | +100.0% | 0.17% | – |
CLVR | New | CLEVER LEAVES HOLDINGS INC | $28,730,000 | – | 2,478,079 | +100.0% | 0.17% | – |
BIIB | New | BIOGEN INC | $25,221,000 | – | 103,000 | +100.0% | 0.15% | – |
CNST | New | CONSTELLATION PHARMCETICLS I | $21,600,000 | – | 750,000 | +100.0% | 0.13% | – |
BEKE | Buy | KE HLDGS INCsponsored ads | $21,108,000 | +2.8% | 343,000 | +2.4% | 0.13% | -10.6% |
New | IQIYI INCnote 4.000%12/1 | $20,000,000 | – | 20,000,000 | +100.0% | 0.12% | – | |
ZEAL | Buy | ZEALAND PHARMA A/Ssponsored adr | $18,329,000 | -4.5% | 510,000 | +1.0% | 0.11% | -17.3% |
INBX | Buy | INHIBRX INC | $16,815,000 | +136.5% | 510,000 | +29.1% | 0.10% | +106.1% |
PRAX | New | PRAXIS PRECISION MEDICINES I | $13,755,000 | – | 250,000 | +100.0% | 0.08% | – |
New | NUANCE COMMUNICATIONS INCdbcv 1.000%12/1 | $13,052,000 | – | 7,000,000 | +100.0% | 0.08% | – | |
XPO | New | XPO LOGISTICS INC | $13,112,000 | – | 110,000 | +100.0% | 0.08% | – |
NTLA | New | INTELLIA THERAPEUTICS INC | $12,240,000 | – | 225,000 | +100.0% | 0.07% | – |
TINVU | New | TIGA ACQUISITION CORPunit 99/99/9999 | $11,426,000 | – | 1,080,000 | +100.0% | 0.07% | – |
RCKT | New | ROCKET PHARMACEUTICALS INC | $10,968,000 | – | 200,000 | +100.0% | 0.07% | – |
CASU | New | CASCADE ACQUISITION CORPunit 99/99/9999 | $10,346,000 | – | 990,000 | +100.0% | 0.06% | – |
KNTE | New | KINNATE BIOPHARMA INC | $9,945,000 | – | 250,000 | +100.0% | 0.06% | – |
ALBO | Buy | ALBIREO PHARMA INC | $9,378,000 | +40.5% | 250,000 | +25.0% | 0.06% | +21.7% |
SURF | New | SURFACE ONCOLOGY INC | $9,240,000 | – | 1,000,000 | +100.0% | 0.06% | – |
New | GOSSAMER BIO INCnote 5.000% 6/0 | $9,032,000 | – | 10,000,000 | +100.0% | 0.05% | – | |
ACIA | Buy | ACACIA COMMUNICATIONS INC | $7,296,000 | +80.4% | 100,000 | +66.7% | 0.04% | +57.1% |
COGT | New | COGENT BIOSCIENCES INC | $6,738,000 | – | 600,000 | +100.0% | 0.04% | – |
FPRX | New | FIVE PRIME THERAPEUTICS INC | $6,804,000 | – | 400,000 | +100.0% | 0.04% | – |
IMGN | New | IMMUNOGEN INC | $6,450,000 | – | 1,000,000 | +100.0% | 0.04% | – |
CRIS | New | CURIS INC | $5,938,000 | – | 725,000 | +100.0% | 0.04% | – |
MRVL | New | MARVELL TECHNOLOGY GROUP LTDcall | $5,943,000 | – | 125,000 | +100.0% | 0.04% | – |
STTK | New | SHATTUCK LABS INC | $5,241,000 | – | 100,000 | +100.0% | 0.03% | – |
TGTX | New | TG THERAPEUTICS INC | $5,202,000 | – | 100,000 | +100.0% | 0.03% | – |
HMCOU | New | HUMANCO ACQUISITION CORPunit 12/08/2023 | $4,408,000 | – | 400,000 | +100.0% | 0.03% | – |
MASS | New | 908 DEVICES INC | $4,271,000 | – | 75,000 | +100.0% | 0.03% | – |
FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $4,145,000 | – | 100,000 | +100.0% | 0.02% | – |
KURA | New | KURA ONCOLOGY INC | $4,083,000 | – | 125,000 | +100.0% | 0.02% | – |
New | ISIS PHARMACEUTICALS INC DELnote 1.000%11/1 | $2,733,000 | – | 2,500,000 | +100.0% | 0.02% | – | |
SBTX | New | SILVERBACK THERAPEUTICS INC | $2,207,000 | – | 47,620 | +100.0% | 0.01% | – |
CEREW | New | CEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202 | $758,000 | – | 134,175 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
GRIFOLS S A | 33 | Q4 2021 | 0.9% |
ALPHABET INC | 32 | Q3 2023 | 4.2% |
SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
VISA INC | 30 | Q3 2023 | 2.9% |
WABTEC CORP | 27 | Q3 2023 | 3.6% |
EXELIXIS INC | 27 | Q3 2023 | 2.8% |
ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
Solid Power, Inc. | February 11, 2022 | ? | ? |
Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR/A | 2024-02-14 |
13F-HR/A | 2024-02-14 |
13F-HR/A | 2024-02-14 |
13F-HR/A | 2024-02-14 |
13F-HR/A | 2024-02-14 |
13F-HR/A | 2024-02-14 |
13F-HR | 2024-02-14 |
13F-HR/A | 2024-02-12 |
SC 13G/A | 2024-02-01 |
SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.